Skip to main navigation Skip to search Skip to main content

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

  • K. L. Moek
  • , W. M. Fiedler
  • , J. C. von Einem
  • , H. M. Verheul
  • , T. Seufferlein
  • , D. J. de Groot
  • , V. Heinemann
  • , M. Kebenko
  • , C. W. Menke-van der Houven van Oordt
  • , T. J. Ettrich
  • , E. Rasmussen
  • , P. Bogner
  • , B. Sable
  • , S. Stienen
  • , E. G.E. de Vries
  • University of Groningen
  • University of Hamburg
  • Ludwig Maximilian University of Munich
  • Ulm University
  • Amgen Incorporated

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)viii139-viii140
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - 1 Oct 2018

Cite this